Pharma Journalist -

Genprex, Inc. has strengthened the intellectual property protection surrounding its lead drug candidate, REQORSA® Gene Therapy, with the announcement that the U.S. Patent and Trademark…
Read More...

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing next-generation targeted cancer…
Read More...

Biogen announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a unanimous positive opinion recommending approval of a high-dose…
Read More...

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech developing oral, targeted cancer therapies using its proprietary…
Read More...

Merus N.V. and Halozyme Therapeutics have entered into a global, non-exclusive collaboration and license agreement to develop and potentially commercialize a subcutaneous formulation of…
Read More...

Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumors, has secured $120 million in an oversubscribed and…
Read More...

Sofinnova Partners, one of Europe’s leading life sciences venture capital firms, has closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million)—substantially…
Read More...

Sarepta Therapeutics has announced significant updates to the U.S. prescribing information for ELEVIDYS, the only approved gene therapy for Duchenne muscular dystrophy (DMD). The…
Read More...

The FDA’s approval of KOMZIFTI™ (ziftomenib) represents a significant milestone for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring NPM1 mutations—one…
Read More...

Eisai and Biogen announced that the UK Medicines and Healthcare products Regulatory Agency has approved a once-every-four-weeks IV maintenance dosing regimen for Leqembi (lecanemab), an…
Read More...